Equities

Avacta Group PLC

AVCT:LSE

Avacta Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)60.50
  • Today's Change0.50 / 0.83%
  • Shares traded742.88k
  • 1 Year change28.72%
  • Beta1.3712
Data delayed at least 20 minutes, as of Feb 06 2026 17:09 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.

  • Revenue in GBP (TTM)-11.09m
  • Net income in GBP-33.09m
  • Incorporated2003
  • Employees151.00
  • Location
    Avacta Group PLCUnit 20, Ash WayWETHERBY LS23 7FAUnited KingdomGBR
  • Phone+44 19 0421 7070Fax+44 84 4414 0453
  • Websitehttps://avacta.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Skinbiotherapeutics PLC4.64m-696.25k54.37m41.0054.37m41.00
Hemogenyx Pharmaceuticals PLC0.00-7.81m59.93m16.0059.93m16.00
4Basebio PLC1.78m-14.41m87.02m--87.02m--
Bioventix PLC13.12m7.58m90.91m16.0090.91m16.00
Scancell Holdings Plc4.71m-5.51m134.91m60.00134.91m60.00
Faron Pharmaceuticals Oy0.00-26.94m188.15m25.00188.15m25.00
Avacta Group Plc-11.09m-33.09m264.25m151.00264.25m151.00
Puretech Health PLC4.73m37.47m309.84m56.00309.84m56.00
Oxford BioMedica plc151.21m-37.07m981.32m900.00981.32m900.00
Data as of Feb 06 2026. Currency figures normalised to Avacta Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

21.29%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Fund Managers Ltd.as of 01 Oct 202535.35m8.10%
Conifer Management LLCas of 05 Jun 202511.66m2.67%
Lombard Odier Asset Management (Europe) Ltd.as of 05 Jun 202511.66m2.67%
IG Markets Ltd.as of 01 Oct 202511.40m2.61%
HSBC Global Asset Management (UK) Ltd.as of 01 Oct 20257.08m1.62%
Unicorn Asset Management Ltd.as of 01 Oct 20254.30m0.99%
AXA Investment Managers UK Ltd.as of 31 Dec 20253.41m0.78%
Evelyn Partners Investment Management Services Ltd.as of 01 Oct 20253.02m0.69%
HSBC Bank Plc (Market-Maker)as of 01 Oct 20252.97m0.68%
Rathbones Investment Management Ltd.as of 01 Oct 20252.06m0.47%
More ▼
Data from 31 Mar 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.